Af­ter first-line ap­proval in DL­B­CL, de­bate con­tin­ues around ben­e­fit from Roche's ADC Po­livy

The FDA ap­proved Roche and Genen­tech’s an­ti­body-drug con­ju­gate Po­livy in April as a first-line treat­ment for dif­fuse large B-cell lym­phoma (DL­B­CL) along­side a chemother­a­py …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.